Please assess the completion status of the following clinical trial:

Trial Title: Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tumor tissue available from primary or nodal metastasis for histological analysis.~* High p16 tumor expression by IHC, or indeterminate p16 expression by IHC and definitively positive detection of high-risk HPV infection by ISH.~* T-stage = T1-3 or post-tonsillectomy Tx (T1-3).~* N-stage = N1-2 or Nx (N1-2).~* Biopsy-confirmed oropharyngeal primary site.~* Histology = squamous cell carcinoma, basaloid-squamous carcinoma, nasopharyngeal-type squamous carcinoma, adenosquamous carcinoma, or papillary squamous carcinoma.~* Age \> 17 years old.~* Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (AGC at least 1500 cells/mm3 and platelet count at least 100,000 cells/mm3); adequate hepatic function with bilirubin less than 1.5x ULN (excluding Gilbert's disease); SGOT, SGPT and alkaline phosphatase must be within the normal range to be eligible for study.~* Creatinine clearance at least 70 ml/min determined by 24 hour collection or nomogram: CrCl male = (140 - age) x (wt in kg)/serum Cr x 72; CrCl female = 0.85 x (CrCl male).~* Patients must have an untransfused hemoglobin of at least 9.0 grams/dL.~* Patients should have no serious acute or chronic co-morbid condition, or acute infection, which in the judgment of the attending physician would affect administration of the induction chemotherapy regimens.~* Patients must sign a study-specific informed consent form.~* All of the above lab criteria must be verified within 28days of registration.~Exclusion Criteria:~* Low p16 expressing tumor by IHC, or indeterminate p16 expression by IHC and negative or weak detection of high-risk HPV infection by ISH.~* TxNx without residual measurable disease, T4, or N3 disease.~* Significant cigarette smoking history, defined as \>10 pack-years total lifetime exposure. Pack years is calculated as # packs smoked per day x # years smoking.~* Histology other than squamous cell carcinoma.~* Proven distant metastases (below the clavicle) by clinical or radiographic measures.~* Karnofsky performance status \< 80 or ECOG \>1.~* Prior chemotherapy, within the previous 3 years.~* Prior radiotherapy to the head and neck.~* Initial surgical resection rendering the patient clinically and radiologically disease free.~* Simultaneous primary invasive cancers, excluding superficial non-melanoma skin cancers.~* Patients with a history of another malignancy (excluding non melanoma skin cancers, and cancers treated \> 3 years prior for which patient remains continuously disease free).~* Men and women of childbearing potential (WOCBP) unwilling to consent to using effective contraception while on treatment and for at least 3 months thereafter. Note: WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for 3 months after the study in such a manner that the risk of pregnancy is minimized.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy non-responders (Type: ACTIVE_COMPARATOR): Patients treated with three cycles neoadjuvant chemotherapy who do not exhibit response to chemotherapy are then allocated to recieve standard dose and schedule radiotherapy.
- Chemotherapy responders (Type: EXPERIMENTAL): Patients who respond to chemotherapy are treated with reduced dose radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).